Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
NCT04372082 · University Hospital, Lille · PHASE3 · withdrawn · last registry update 2021-03-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “evidence showed chloroquine is not effective against COVID-19” | – | Registry record, University Hospital, Lille |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TLR7 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-11Results posted on the registry: The Cleveland Clinic, Hydroxychloroquine + Placebo (NCT03283566)
- 2022-02-21Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Hydroxychloroquine + low-dose prednisone + Prednisone (NCT05247554)
- 2022-02-14Also stopped (terminated): University of New Mexico, Hydroxychloroquine (NCT04435808)
- 2022-01-21Also stopped (terminated): LCMC Health, Hydroxychloroquine + Azithromycin (NCT04344444)
- 2022-01-03Results posted on the registry: University of South Alabama, Hydroxychloroquine (NCT04353271)
- 2022-01-03Also stopped (terminated): University of South Alabama, Hydroxychloroquine (NCT04353271)
- 2021-12-16Results posted on the registry: University of Sao Paulo General Hospital, Thalidomide + Hydroxychloroquine reduced (NCT03122431)
- 2021-12-16Results posted on the registry: University of Washington, Hydroxychloroquine Sulfate + Ascorbic Acid (NCT04328961)
- 2021-12-15Also stopped (terminated): University Hospital, Montpellier, Hydroxychloroquine + placebo + hydroxychloroquine + azithromycin (NCT04345861)
- 2021-12-10Results posted on the registry: Sanford Health, Hydroxychloroquine (NCT04372017)
- 2021-12-10Also stopped (terminated): Sanford Health, Hydroxychloroquine (NCT04372017)
- 2021-12-07Also stopped (withdrawn): International Brain Research Foundation, Hydroxychloroquine + Azithromycin (NCT04590274)
- 2021-11-16Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Hydroxychloroquine (HCQ) + Azithromycin (Azithro) (NCT04358068)
- 2021-11-03Results posted on the registry: Imperial College London, a drug against TLR7 (NCT02090374)
- 2021-10-28Also stopped (withdrawn): Iterum Therapeutics, International Limited, Azithromycin plus hydroxychloroquine (NCT05026801)
- 2021-10-27Results posted on the registry: Memorial Sloan Kettering Cancer Center, Hydroxychloroquine (NCT04381988)
- 2021-10-27Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Hydroxychloroquine (NCT04381988)
- 2021-10-26Also stopped (withdrawn): King Hussein Cancer Center, HCQ & AZ (NCT04354597)
- 2021-10-20Phase 3 first posted: University Hospital, Toulouse, Hydroxychloroquine (NCT05084872)
- 2021-10-19Results posted on the registry: UnitedHealth Group, Group 1 HCQ + Group 2 Placebo (NCT04353037)
- 2021-10-19Also stopped (terminated): UnitedHealth Group, Group 1 HCQ + Group 2 Placebo (NCT04353037)
- 2021-10-07Results posted on the registry: Adrian Hernandez, Hydroxychloroquine + Placebo oral tablet (NCT04334148)
- 2021-10-06Results posted on the registry: NYU Langone Health, Hydroxychloroquine (HCQ) (NCT04354870)
- 2021-09-27Also stopped (withdrawn): St. Joseph's Healthcare Hamilton, Apo-Hydroxychloroquine + Matched Placebo (NCT04371523)
- 2021-09-23Also stopped (terminated): Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., UNIKINON (Chloroquine phosphate) 200mg tablets (NCT04344951)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision